DR. PIERRE DEBS, PH.D.
CEO of Canopy’s German division, Spektrum Cannabis Germany GmbH, Managing Director of Canopy Growth (Europe)
Dr. Debs is a renowned stem cell biologist with over 25 years research experience with genetic engineering, stem cell biology, somatic cell reprogramming and the endocannabinoid system at world class research universities in the US and Europe. His extensive academic research incudes studying the human body’s endocannabinoid system. After a family member with cancer began successfully self-medicating with cannabis extracts, Dr. Debs co-founded MedCann GmbH with the goal to produce cannabis medicines giving German patients more choices, to drive medical cannabis awareness and support clinical research.
In July 2016, MedCann began importing medical cannabis from Canada and started distribution to German pharmacies. In late 2016, MedCann was acquired by Canopy Growth Corporation. With Dr. Debs continuing as CEO, the company has since been re-named Spektrum Cannabis Germany GmbH.
After a family member with cancer began successfully self-medicating with cannabis extracts, Dr. Debs started searching scientific literature for clues as to why full spectrum cannabis extracts were helping, and found very little. At the same time, he started studying the endocannabinoid system in cancer cells culture, then in various stem cells. In 2015 he left the lab and co-founded MedCann GmbH with the goal to produce cannabis medicines giving German patients more choices, to drive medical cannabis awareness and support clinical research. By the end of July 2016, MedCann had successfully imported medical cannabis from Canada and started distribution to German pharmacies. Going from biological research direct to CEO of a cannabis start-up is an interesting adventure, more so in Germany. By the end of 2016, MedCann was acquired by Canopy Growth Corporation underscoring the importance of Germany to the growing European cannabis industry.
About Canopy Growth Corporation (TSX: WEED)
Canopy Growth Corporation, formerly Tweed Marijuana Inc., is a medical marijuana company based in Smiths Falls, Ontario, founded by Bruce Linton and Chuck Rifici in 2014. Canopy Growth advances the world’s perception of cannabis by focusing on research, product development and innovative production capabilities.
Chief Corporate Officer, Aurora Cannabis (ACB)
Cam Battley is the chief corporate officer of Aurora Cannabis, one of the world’s largest and fastest growing cannabis companies. A passionate spokesperson for the medical cannabis industry, he started with Aurora Cannabis in March 2016 and has been a key driver to Aurora’s emergence as a global leader.
As a senior healthcare industry leader and strategist with more than 20 years of international experience, Mr. Battley is the lead external-facing executive of Aurora, responsible for establishing and managing relationships with shareholders, analysts, media, regulators, governments, and other companies and organizations operating in the cannabis sector.
About Aurora Cannabis (TSX: ACB)
Headquartered in Edmonton, Alberta, with funded capacity in excess of 570,000 kg per year and sales and operations in 14 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies.
CEO, Director, Wayland Group (formerly Maricann Group Inc. (MARI)
Mr. Ward leads all facets of operations for Wayland Group (formerly Maricann Group), including its strategic direction and execution, finance and industry relations. He brings extensive domestic and global experience in business development, infrastructure development and capital markets to his leadership of Wayland Group.
Ben holds a BA (Honors) and an MBA from Bradford University School of Management (England), the latter with a dual concentration in Operations and Finance.
About Wayland Group(formerly Maricann (CSE: MARI)
Wayland Group is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ont., Canada, and Munich, Germany, with production facilities in Langton, Ont., where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the government of Canada.
The company also has production operations in Dresden, Saxony, Germany, and Regensdorf, Switzerland. Wayland Group is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000-square-foot (87,515 square metres) and will continue to pursue new opportunities in Europe.
President & CEO, Aphria Inc.
Vic Neufeld is the former CEO of Jamieson Laboratories, Canada’s largest manufacturer and distributor of natural vitamins, minerals, concentrated food supplements, herbs and botanical medicines. He brings 15 years of experience as a chartered accountant and partner with Ernst & Young and 21 years as CEO of Jamieson.
During his tenure with Jamieson, the company went from $20 million in annual sales to over $250 million and expanded the company’s distribution network to over 40 countries, building Jamieson to a globally recognized name.
Mr. Neufeld, a native of Leamington, Ontario, earned a Bachelor’s degree in economics from Western University, an honours degree in business, as well as an MBA, from the University of Windsor. Mr. Neufeld is a chartered professional accountant (CPA).
About Aphria Inc. (TSX: APH)
Aphria is a leading global cannabis company driven by an unrelenting commitment to its people, product quality and innovation. Headquartered in Leamington, Ont. — the greenhouse capital of Canada — Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible.
Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The company’s portfolio of brands is grounded in expertly researched consumer insights designed to meet the needs of every consumer segment.
FRANJO GROTENHERMEN, MD
Founder, Chairman, German Association for Cannabis as Medicine (ACM); Founder and Executive Director, International Association for Cannabinoid Medicines (IACM); chairman of the Medical Cannabis Declaration (MCD)
Franjo Grotenhermen, MD, studied academic medicine at the University of Cologne. He runs a medical practice, mainly devoted to the medical use of cannabis and cannabinoids.
He is editor of the IACM-Bulletin, which is published bi-weekly in several languages and editor of the internet journal CANNABINOIDS, published on the website of the IACM. He is a principal of the Nova Institute, based near Cologne, and author of many articles, books and book chapters on the therapeutic potential, pharmacology and toxicology of the cannabinoids.
VP Investor Relations, The Green Organic Dutchman Holdings Ltd. (TGOD)
Mr. Brody has more than a decade’s experience in finance and holds a Chartered Investment Manager (CIM) designation from the Canadian Securities Institute (CSI).
During his previous career in the stock brokerage industry, he developed invaluable skills in the areas of fundraising, business development, database management and marketing – all of which he is successfully applying to the cannabis industry. Danny has conducted presentations at various conferences around the world specializing in finance and cannabis, including Asia, Europe, and throughout North America.
About the Green Organic Dutchman (TSX: TGOD)
The Green Organic Dutchman Holdings grows high-quality, organic cannabis with sustainable, all-natural principles. The company’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. Also known as “TGOD”, the Ontario-based company is on-track to become the world’s largest grower of pharmaceutical-grade, premium-quality organic cannabis.
SEBASTIEN ST. LOUIS
Co-founder & Chief Executive Officer of HEXO Corp.
Sébastien St. Louis is an entrepreneur with strong leadership abilities, financial acumen and operational expertise. Sébastien has wide-ranging business experience in manufacturing, distribution, trade finance and commercial lending. He has advised Canadian business owners and CEOs across multiple industry sectors, while structuring and closing $200 million in financing to support their export and growth initiatives.
Sébastien co-founded HEXO Corp. with one goal in mind: to create a world-class company based on the highest standards of product quality and safety. Since 2013, he has secured more than $260 million dollars in financing for the company.
His leadership has been instrumental in navigating the company through regulatory, financing and start-up challenges on route to becoming the only significant licensed cannabis producer in Quebec and, upon completion of two fully-funded expansion projects currently underway, one of the largest in Canada. Sébastien holds an MBA in Finance from the Université du Québec à Montréal and completed his Bachelor of Arts (Economics) from the University of Ottawa in 18 months.
About HEXO Corp. (formerly Hydropothecary) (TSX: HEXO)
HEXO Corp. creates and distributes innovative, easy-to-use and easy-to-understand products to serve the Canadian cannabis market. One of the country’s lowest-cost producers, HEXO is rapidly increasing its production capacity in the lead up to the adult-use cannabis market.
The Company currently operates with 310,000 sq. ft. of production capacity with construction on another 1,000,000 square feet expansion set to be complete by year end. HEXO will serve the adult-use market under the HEXO brand, while continuing to serve its medical cannabis clients through the well-known Hydropothecary brand.
CEO and Director, Emerald Health Therapeutics Inc.
Chris has more than 25 years’ experience in commercialization and product development in the life sciences industry. As the Global Team Leader at Eli Lilly, Chris launched 15 biologic and small molecule products and directed global marketing for several notable brands, including Prozac, Cialis and Zyprexa, which alone achieved annual sales of over $4 billion per year.
He left Eli Lilly to join Asperva Pharmaceuticals Inc. as Vice President, Business Development and Global Markeing. During his five years, at Aspreva, the company’s valuation increased from $2 million to $1 billion; it was later acquired by Galenica.
About Emerald Health Therapeutics (TSX.V: EMH)
Emerald Health is a Health Canada licensed producer of medical cannabis. With extensive expertise from the pharmaceutical and biotechnology industries, conventional and naturopathic medicine, and natural health products, Emerald approaches the cannabis and cannabinoid opportunity through a life sciences lens. Emerald also has global-scale consumer products marketing and agriculture expertise. While vertically integrated, and joint ventured with one of North America’s largest greenhouse growers on a sophisticated, nearly-completed 103,000 square metre greenhouse, one of the largest growing facilities in Canada, Emerald Health is focused on the opportunities to develop value-added products that are differentiated in form, delivery and applications.
Emerald recently established a unique strategic alliance with the Factors Group, the largest natural health products company in Canada and which also has sales in 50 countries. This deal provides Emerald with access to Factors’ extensive experience and infrastructure related to extraction (1 million kilograms of annual processing capacity) and softgel encapsulation (600 million capsules annually). Emerald also announced an agreement to secure CBD-rich hemp harvest from 400 hectares of land in 2018 and 800+ hectares beyond.
CEO and Director of Rubicon Organics
As an authority with nearly two decades of experience in the Cannabis industry, Jesse co-founded the first certified organic, federally-licensed cannabis growing facilities in Canada. He has an unparalleled network of relationships in the industry and has been involved in the design and licensure of multiple facilities across Canada and the United States.
Jesse’s industry experience also includes the development of proprietary, innovative growth techniques to produce high-quality certified organic cannabis crops. In a previous life Jesse was a university educated economist and philosopher.
About Rubicon Organics Inc.
Rubicon Organics is a vertically integrated cannabis company with operations in Canada, California and Washington. The Company holds the intellectual property to produce low-cost, premium quality Certified Organic Cannabis.
Rubicon is working towards beginning cultivation in Q3 2018 with a combined Phase I capacity of 15,400 kg and planned expansion to 82,000 kg by 2020. The Company has two rapidly growing cannabis brands: 1964 Supply Co.TM in California and Doctor & Crook Co.TM in Washington sold by a state licensed processor.
CEO and Director of Khiron Life Sciences Corp.
Alvaro has over 15 years of experience in the Latin American market, including infrastructure projects and project finance, management strategy, team development, and mergers and acquisitions.
He was previously head of business development for SNC-Lavalin, Colombia, and was instrumental in growing the company from two people to more than 2,000 people in Colombia over the course of three years.
He has overseen the development of projects totaling over $1 billion in capital expenditure, including the development and construction of Colombia’s tallest skyscraper. Mr. Torres holds a Bachelor of Engineering and a Masters of Engineering from Rensselaer Polytechnic Institute and an MBA from Georgetown University.
About Khiron Life Sciences (TSX.V: KHRN)
Khiron Life Sciences is positioned to be a leading integrated medical cannabis company in Latin America. The company has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May, 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian-based medical cannabis company to trade on any exchange globally.
Co-Founder, CEO and Director of Ascent Industries
With an unparalleled level of industry knowledge in the medical and recreational cannabis space both in Canada and the United States, Philip touches all aspects of the Ascent organization and leads in a variety of ways.
Having already co-founded a successful entrepreneurial endeavor in the tech space, Philip brings a wealth of expertise to Ascent, including a strong background in business, marketing and essential hands-on experience in the production and engineering side of the cannabis industry. Philip holds a Bachelor of Business Administration with a major in Marketing from Simon Fraser University.
About Ascent Industries Corp. (CSE: ASNT)
In Canada, Ascent Industries (through its wholly owned subsidiaries) is a licensed producer under the Access to Cannabis for Medical Purposes Regulations of Health Canada, with licences to cultivate cannabis and produce cannabis extracts.
In addition, the company is a licensed dealer under the Controlled Drugs and Substances Act (Canada), with the ability to produce, package, sell, send, transport and distribute medically focused cannabis products in Canada to other licensed entities (and internationally in jurisdictions where medical cannabis is legal).
In the United States, the company holds licences in Oregon (for processing and for distribution of cannabis to any licensed entity in the state) and in Nevada (for cultivation as well as production, processing and wholesale distribution of cannabis).
The company’s operations currently include licensed facilities in British Columbia, Canada, and in Oregon and Nevada in the U.S.
Founder & CEO and Board Member of Pure Global Cannabis Inc.
Malay (Mel) is a seasoned serial-entrepreneur with 20+ years experience in pharma B2B technology, retail and mail-order pharmacy, pharma branding and clinical trials. He is Founder and CEO of Pure Global Cannabis Inc. and PureSinse Inc. (TSX.V:PURE, OTC:PRCNF), a Licensed Producer under the ACMPR located in Toronto, Ontario. As an experienced pharmaceutical professional, executive, operator, project manager, and marketer, he has a passion for improving patient health outcomes delivered with technological and product innovation. Mel has extensive knowledge and experience in the pharmaceutical, healthcare, medical cannabis, natural medicine, eCommerce, IT, retail and mail order pharmacy sectors.
About Pure Global Cannabis Inc. (TSX.V: PURE)
Pure Global Cannabis is a vertically integrated, growth-oriented life sciences cannabis company led by experienced pharma-industry, horticultural, consumer packaged goods (CPG) and supply chain experts.
The company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR) focused on producing cannabis products for medical, wellness, health and beauty, natural health, and future legal adult use markets.
Pure Global is expecting total production capacity of up to 132,000 KG in Canada and Colombia. The company’s aggregate production footprint is expected to be 904,000 square feet, translating into total production capacity of up to 132,000 KG in Canada & Colombia.
President and COO, CannTrust Holdings Inc.
Brad Rogers is a recognized expert in the business of medical cannabis production and a creative brand-building marketer. Known for building high-performing teams, Mr. Rogers is responsible for the planning and execution of brand-growth strategies to ensure valued CannTrust customers receive the very best products and support.
Prior to joining CannTrust, Mr. Rogers gained extensive experience in Medical Cannabis as one of the founders of Mettrum, one of Canada’s largest industrial-scale licensed companies, which was acquired by Canopy Growth for CDN $430 million.
About Canntrust Holdings Inc. (CSE: TRST)
As a federally regulated licensed producer, Canntrust brings more than 40 years of pharmacy and health care experience to the medical cannabis industry. Canntrust currently operates the recently completed 250,000-square-foot phase one redevelopment of its 450,000-square-foot Niagara Perpetual harvest facility.
CannTrust has invested in its state-of-art hydroponic facility and onsite laboratory equipped with leading-edge technology, and has an exceptional team of pharmacists, nurses, scientists, laboratory technicians, master growers and call centre specialists.
Former FDP Leader
Birgit Homburger is the recent past Chair of the Freie Demokratische Partei (parliamentary group FDP), member of the Federal Coalition committee, member of the Bundestag up to 2013, Chairwoman of the FDP parliamentary group in the Bundestag and leader of the parliamentary group with 93 members of the German Bundestag, responsible for over 110 staff.
She is currently head the Berlin office for the Deutsche Aktieninstitut e. V (an institute representing publicly traded companies, investors and banks, and she is a senior advisor in an international executive search company.